Last reviewed · How we verify
Peripheral blood puncture
At a glance
| Generic name | Peripheral blood puncture |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Treatment of Hemochromatosis (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia (PHASE2)
- Disorders of the Acute Phase Response Following Trauma and Invasive Surgery (NA)
- Characterization Phenotypic and Genetic Study of the Intestinal Epithelial Dysplasia or Tufting Enteropathy (TE) (NA)
- Prognostic Interest of Vasorin in Septic Shock (NA)
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peripheral blood puncture CI brief — competitive landscape report
- Peripheral blood puncture updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI